To the Editor: Dialogue on the design, conduct, analysis, and reporting of comparative effectiveness research is important for formulating valid treatment guidance and ensuring effective and efficient health care resource utilization. The analysis by Barnett et al 1 assessed the cost-effectiveness of long-acting injectable (LAI) risperidone versus physician's choice of oral antipsychotics in Veterans Health Administration patients with unstable schizophrenia or schizoaffective disorder. The study on which this analysis was based (Rosenheck et al 2 ) was partly funded by our company. We fully support research characterizing our products' efficacy, safety, appropriate use, and cost-effectiveness. However, aspects of this analysis and its interpretation warrant discussion.
entered the study as intense users of care, with 54 visits in the year prior to randomization. They had 66 visits per year during the trial. The acute instability that made them eligible for the trial may account for much of this increase in service use.
It has been hypothesized that the extra cost of injectable antipsychotic medications like LAI risperidone will be offset by reduced psychiatric hospitalization costs. We determined that patients randomly assigned to LAI risperidone had higher medication cost, but we found no significant offset.
This study was not designed to show the equivalence of LAI risperidone and oral antipsychotics. Its findings were consistent with 4 previous trials that found no significant superiority for LAI risperidone as compared to oral agents. [3] [4] [5] [6] A fifth trial that found an advantage to LAI risperidone may have used less-than-optimal doses of the oral comparator. 7 Adoption of a more costly medication can be justified only if it increases value. We found that LAI risperidone increased pharmaceutical costs without offsetting other costs or generating any therapeutic benefit. Health care sponsors will be hard-pressed to include LAI risperidone in their formulary when it cannot show a significant benefit in repeated trials.
